SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infection, progression, non-progression, response to treatment, control of HIV-1 virus, and evolution of drug resistance.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ SCOPE is currently recruiting HIV-1 infected subjects with any of the following criteria:

• Documented HIV viral load less than 2000 copies/ml WITHOUT taking antiretroviral therapy

• Undetectable HIV viral load with CD4 T-cells consistently less than 350 for the last 12 months while taking a stable antiretroviral regimen.

• Antiretroviral naive and planning to start an antiretroviral regimen - any CD4 or HIV viral load acceptable.

• Long-term Non Progressors: HIV-positive at least 10 years, no antiretroviral therapy for the past 10 years or more, any viral load acceptable, CD4-T cell count always above 500.

Locations
United States
California
San Francisco General Hospital
RECRUITING
San Francisco
Contact Information
Primary
Rebecca Hoh, M.S., R.D.
Rebecca.Hoh@ucsf.edu
415-476-4082
Backup
Montha Pao
Montha.Pao@ucsf.edu
415-476-4082
Time Frame
Start Date: 2000-03
Estimated Completion Date: 2033-12
Participants
Target number of participants: 2500
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Leads: University of California, San Francisco

This content was sourced from clinicaltrials.gov